SCHEMBL25494271

SCHEMBL25494271

Cc1cc(C(C)C)ccc1NC(=O)NC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.45
▸ KMT2A Q03164 7/20 0.45
▸ MAPK1 P28482 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ MYOC Q99972 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ LMNA P02545 1/20 0.40
▸ TRPA1 O75762 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ CACNA1C Q13936 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ CASP7 P55210 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25494267 0.85 MEN1 (0.47) MEN1KMT2AMAPK1MAPTPOLB
SCHEMBL25494282 0.82 POLB (0.64) MEN1KMT2AMAPK1MAPTNPSR1
SCHEMBL25494287 0.81 TP53 (0.44) MEN1KMT2AMAPK1MAPTNPSR1
SCHEMBL25497035 0.81 MAPK1 (0.50) MEN1KMT2AMAPK1MAPTNPSR1
SCHEMBL12190515 0.79 ALDH1A1 (0.52) MEN1KMT2AMAPK1MAPTNPSR1
SCHEMBL6975862 0.78 RAF1 (0.42) MEN1KMT2AMAPK1NPSR1POLB
SCHEMBL11409006 0.77 POLB (0.44) MEN1KMT2AMAPK1MAPTNPSR1
SCHEMBL9979294 0.76 MAPT (0.52) MEN1KMT2AMAPTNPSR1MYOC
SCHEMBL25494260 0.76 RAB9A (0.64) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL18930354 0.75 TRPA1 (0.41) MEN1KMT2AMAPK1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 — — US disclosed
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 — — US disclosed
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 — — US disclosed
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates LYCIA THERAPEUTICS, INC. 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates M6PR, ASGR1, IGF2R MEN1 1529/4885KMT2A 2580/4885MAPK1 2043/4885
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, FCGR3B, FCGR2A MEN1 1824/4885KMT2A 3875/4885MAPK1 3302/4885
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, ASGR1, FCGR3B MEN1 2803/4885KMT2A 3255/4885MAPK1 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback